Cantor Fitzgerald Forecasts Codexis FY2025 Earnings

Codexis, Inc. (NASDAQ:CDXS) – Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Codexis in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska expects that the biotechnology company will post earnings per share of ($0.51) for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $11.00 target price on the stock. The consensus estimate for Codexis’ current full-year earnings is ($0.77) per share.

Codexis (NASDAQ:CDXS) last posted its quarterly earnings results on Thursday, October 31st. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.04). The company had revenue of $12.83 million during the quarter, compared to the consensus estimate of $11.64 million. Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. During the same period last year, the firm posted ($0.26) earnings per share.

Separately, Benchmark restated a “hold” rating on shares of Codexis in a report on Monday, November 4th.

Codexis Stock Up 2.3 %

CDXS stock opened at $4.98 on Thursday. The stock’s 50 day simple moving average is $4.88 and its 200 day simple moving average is $3.79. The company has a market cap of $405.27 million, a P/E ratio of -5.72 and a beta of 2.13. The company has a debt-to-equity ratio of 0.39, a quick ratio of 3.15 and a current ratio of 3.21. Codexis has a fifty-two week low of $2.53 and a fifty-two week high of $6.08.

Hedge Funds Weigh In On Codexis

Hedge funds have recently added to or reduced their stakes in the stock. Kingswood Wealth Advisors LLC purchased a new stake in shares of Codexis in the fourth quarter worth approximately $79,000. Intech Investment Management LLC purchased a new stake in Codexis in the 3rd quarter valued at $66,000. Marshall Wace LLP bought a new position in Codexis during the 2nd quarter valued at $89,000. Algert Global LLC boosted its holdings in Codexis by 17.1% during the 2nd quarter. Algert Global LLC now owns 41,556 shares of the biotechnology company’s stock worth $129,000 after acquiring an additional 6,069 shares during the last quarter. Finally, Jackson Square Capital LLC bought a new stake in shares of Codexis in the 4th quarter worth $210,000. Institutional investors and hedge funds own 78.54% of the company’s stock.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.